Unleashing economic potential of AI-driven technology to prevent adverse events and sub-optimal treatment [0.03%]
释放人工智能驱动技术的经济潜力以预防不良事件和次优治疗
L Maas,C Contreras-Meca,W Vos et al.
L Maas et al.
Expert review of pharmacoeconomics and outcomes research: high impact articles from 2024 [0.03%]
药物经济学与结果研究专家评论：2024年高影响力文章
Mickaël Hiligsmann,Carolyn Gotay,Jayashri Sankaranarayanan et al.
Mickaël Hiligsmann et al.
Disease burden estimates in economic evaluation studies of respiratory syncytial virus (RSV) maternal immunization: a systematic review [0.03%]
呼吸道合胞病毒(RSV)孕妇免疫经济评估研究中的疾病负担估计值：系统综述
Sophia Aguiar Monteiro Borges,Natacha Regina de Moraes Cerchiari,Erick Ohanesian Polli et al.
Sophia Aguiar Monteiro Borges et al.
Introduction: Recently, new technologies have emerged for the prevention of respiratory syncytial virus (RSV) infections. Reliable epidemiological data are essential for accurately assessing the disease burden and informi...
A cost-effectiveness estimation of the attempted suicide short intervention programme (ASSIP) [0.03%]
自杀未遂短期干预方案的成本效益分析估算
Max Lelie,Riet Parmentier,Eva de Jaegere et al.
Max Lelie et al.
Objective: Patients who have previously attempted suicide are at a substantially increased risk of a repeated attempt. We have conducted a cost-utility analysis of the Attempted Suicide Short Intervention Programme (ASSIP...
Transdisciplinary health economics for 2050: the challenge of preventing the adverse health effects of obesity, inequalities, and climate change [0.03%]
面向2050年的跨学科卫生经济学：防治肥胖、不平等和气候变化所致不良健康效应的挑战
Rhiannon Tudor Edwards
Rhiannon Tudor Edwards
Bram Wouterse,Joao Vasco Santos,Mickaël Hiligsmann
Bram Wouterse
Won Chan Lee,Chris Blanchette,Shibani Pokras et al.
Won Chan Lee et al.
Introduction: Integrated Evidence Planning (IEP) is a strategic approach that optimizes drug development by ensuring evidence generation aligns with regulatory, clinical, and market needs. The increasing integration of ad...
Access to medicines, care, and services for multiple sclerosis patients in central and eastern European countries: a comparative analysis [0.03%]
中欧和东欧国家多发性硬化症患者的医药、护理及服务可及性的比较分析
Yoana Seitaridou,Dominik Grega,Sorin Paveliu et al.
Yoana Seitaridou et al.
Background: The study compared access to disease-modifying treatments (DMTs), care, and services for multiple sclerosis (MS) patients across six Central and Eastern European Countries (CEECs). ...
Consumption and expenditure of drugs used for the treatment of hypercholesterolemia: a governance analysis [0.03%]
高胆固醇治疗药物的消费和支出治理分析
Francesco Ferrara,Andrea Zovi,Roberto Langella et al.
Francesco Ferrara et al.
Background: Elevated cholesterol levels are a significant contributor to cardiovascular disease risk. While statins have long been the cornerstone for lowering LDL cholesterol, their associated side effects have prompted ...
Cardiovascular events, mortality, and incident type 2 diabetes in patients with metabolic dysfunction-associated steatohepatitis: a claims-based analysis of commercial and medicare advantage enrollees [0.03%]
代谢功能紊乱相关非酒精性脂肪肝病患者的临床结局：商保及 Medicare 优势计划参保人资料的分析
Semiu O Gbadamosi,Jason P Swindle,Hai Nguyen et al.
Semiu O Gbadamosi et al.
Background: The objective of this study was to examine the risks of cardiovascular events, incident type 2 diabetes (T2D), and mortality in patients with newly diagnosed metabolic dysfunction - associated steatohepatitis ...